|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:bioavailability
|
>60%
|
|
gptkbp:CASNumber
|
gptkb:151096-09-2
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:developedBy
|
gptkb:Merck
|
|
gptkbp:drugClass
|
gptkb:recombinant_human_growth_hormone
ghrelin receptor agonist
|
|
gptkbp:eliminationHalfLife
|
4-6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
gptkb:QZJXODVYFRCQDF-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H36N4O5S
|
|
gptkbp:hasSMILES
|
CC(C)CN(C)CCCN1C=C(C2=CC=CC=C21)C(=O)NC3=CC=CC=C3S(=O)(=O)N
|
|
gptkbp:hasUNII
|
JEV8U1C1YW
|
|
gptkbp:indication
|
gptkb:bone
obesity
muscle wasting
growth hormone deficiency
|
|
gptkbp:isNotApprovedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
stimulates growth hormone release
ghrelin receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
528.7 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL122931
gptkb:DB12189
159633
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
muscle pain
increased appetite
elevated blood sugar
transient edema
|
|
gptkbp:synonym
|
gptkb:Ibutamoren
gptkb:MK-677
|
|
gptkbp:bfsParent
|
gptkb:Avelox
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
151096-09-2
|